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1049-104 Correlation Between Brain Natriuretic Peptide and 
Cardiopulmonary Exercise Test Parameters in Patients 
With Chronic Heart Failure
Angela Beatrice Scardovi, Nadia Aspromonte, Claudio Coletta, Elena Cerquetani, Mauro 
Romano, Tiziana Di Giacomo, Manuela Greggi, Vincenzo Ceci, S. Spirito Hospital, 
Rome, Italy
We sought to evaluate if brain natriuretic peptide ( BNP) levels are associated with exer-
cise capacity determined by cardiopulmonary exercise test ( CPx ) in patients (pts) suffer-
ing from CHF. One-hundred sisty-five consecutive pts with CHF (age 70; beta blockers
53%; ischemic CHF: 52%; mean ejection fraction 41%; NYHA class I: 8%; II: 68 %; III:
24%) were considered. Mean BNP was 228 ± 277 pg/ml ( Biosite Diagnostic, Triage BNP
Test). CPx parameters were: VO2 peak (PVO2) (12,35+4,48 ml/Kg/min), anaerobic
threshold (AT) (9,43±2,80 ml/Kg/min), ventilation and carbon dioxide production ratio
(VE/VCO2) ( 38,02±8,27) , VE/VCO2 slope (33,82±7,78).
Results: A reverse statistically significant correlation between BNP level, PVO2 (r = -
0,297; p < 0,0001) and AT ( r = - 0,271; p<0,05) was respectively observed. A significant
correlation between BNP and abnormally high ventilatory response to exercise,
expressed as VE/VCO2 (r = 0,345; p<0,0001) and VE/VCO2 slope (r = 0,432; p<0,0001)
was observed. The ROC curves demonstrated BNP > 97 pg/ml to be the best cut-off for
determining PVO2 <14 ml/Kg/min, with overall accuracy of 71% (sensitivity: 65%; speci-
ficity: 65%), area under the curve (AUC): 0,69. Moreover, ROC demonstrated BNP > 138
pg/ml to be the best cut-off for determining PVO2 <10 ml/Kg/min, with overall accuracy
62% (sensitivity: 67%; specificity: 64%), AUC 0,72. BNP offers an alternative tool for dis-
tinguishing pts with moderate-to-severe reduction of exercise capacity.
1049-105 Increased Plasma Levels of Nt-ProANP and Nt-ProBrain 
Natriuretic Peptide as Markers of Cardiac Depression in 
Septic Patients
Ursula Hoffmann, Martina Brueckmann, Thomas Bertsch, Claudia Liebetrau, Martin 
Borggrefe, Guenter Huhle, Karl K. Haase, University Clinic Mannheim, Mannheim, 
Germany
Background: The family of natriuretic peptides comprises several structurally-related 22-
53-amino acid peptides, such as atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP), which are vasoacitve peptides that have vasodilator and diuretic properties
and play an important role in cardiovascular homeostasis. The salutary cardiovascular
effects of natriuretic peptides suggest that ANP and BNP have a pathophysiological sig-
nificance in cardiac depression in septic patients. Aim of the present study was to deter-
mine plasma levels of the stable N-terminal prohormone forms of ANP (Nt-proANP) and
BNP (Nt-proBNP) in septic patients and healthy controls.
Patients and Methods: Nt-proANP and Nt-proBNP levels were measured in plasma
samples from 18 septic patients at day 1 of severe sepsis and 13 healthy controls by
ELISA- methods.
Results: The mean APACHE-Score of septic patients was 16.8 ± SD= 4.0 on day 1. Ten
of the 18 septic patients died (55% = non-survivors). Significantly higher concentrations
(p=0.006) of Nt-proANP were measured in non-survivors (MW=13415 fmol/l ± SEM =
3640) as compared to controls (MW=2274 fmol/ml ± SEM= 1043). There was also a sig-
nificantly difference between Nt-proANP levels in controls and survivors (p= 0.019).
There were no differences of Nt-proANP levels between survivors and non-survivors
(p=0.189). Levels of Nt-proBNP were also significantly higher in non-survivors
(MW=3439 fmol/l ± SEM=1246; p=0.010) and survivors (MW =1009 fmol/l ± SEM=
263;p=0.001) as compared to controls (MW = 200 fmol/l ± SEM=24). There was no sig-
nificant difference between concentrations of Nt-proBNP in the non-survivor and the sur-
vivor-group.
Conclusion: Nt-proANP and Nt-proBNP levels are elevated in the early course of septic
patients, possibly reflecting myocardial depression in severe sepsis.
1049-106 Endothelial Marker Big Endothelin-1 Is More 
Discriminant Than Brain Natriuretic Peptide to 
Categorize Patients With Congestive Heart Failure
Ronald Van Beneden, Michel P. Hermans, Sylvie A. Ahn, Jean-Marie Ketelslegers, 
Michel F. Rousseau, University of Louvain, Brussels, Belgium
Background: Brain Natriuretic Peptide (BNP) and Big Endothelin-1 (BigET-1) are
becoming central as diagnostic and prognostic neurohormonal markers to the manage-
ment of patients with congestive heart failure.
Methods: The Discriminant Ratio (DR) method (Levy JC et al. Am J Physiol 276: E365-
E375, 1999) was used to compare the respective performance of BNP and BigET-1 to
rank patients according to heart failure severity. The DR estimates the ability of a method
to discriminate subjects. It is obtained from the ratio of the underlying between-subject
standard deviation (SDu) to the within-subject SD (SDw). DRs were calculated from BNP
and BigET-1 duplicates, sampled on 2 consecutive days. Significance of differences in
DRs was p<0.05. Correlation coefficients between pairs of measurements were adjusted
in order to include an estimate of the underlying correlation, since standard coefficients,
due to the presence of within-subject variation, tend to underestimate the true correlation
between tests through attenuation. An unbiased estimation of the linear relationship
equation between methods was also derived.
Results: Plasma concentrations of BNP and BigET-1 were measured in duplicates in 31
heart failure patients (NYHA II–IV, mean EF 23%). Mean values of day 1 and day 2 (±SD)
were 75 (52) and 77 (52) pg/mL for BNP [normal values (range): 5.4 (2.5-12.8) pg/mL],
and 12.5 (7.4) and 12.0 (8.1) pg/mL for BigET-1 [normal values (range): 5.7 (4.0-7.6) pg/
mL], respectively. The difference between the DRs of BNP and BigET-1 (2.73 and 4.61
respectively) was statistically significant (p<0.05) in favor of a better discriminating ability
for BigET-1. Unadjusted Pearson coefficient between methods was 0.70, rising up to 0.83
following adjustment for attenuation. Slope and intercept of the unbiased estimation of
the linear relationship equation between measurements were 0.18 and -1.47 pg/mL,
respectively.
Conclusions: According to the DR method, BigET-1 appears able to better discriminate
a heart failure population than BNP. Although both markers are highly correlated in this
population, BigET-1 is the choice method to categorize patients with congestive heart fail-
ure.
1049-107 Natriuretic Peptides as Predictors of Clinical Course in 
Patients With End-Stage Heart Failure
Evgenij V. Potapov, Frank D. Wagner, Felix Hennig, Christian Müller, Rainer Michael, 
Hans B. Lehmkuhl, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany, 
Charité, Humboldt University, Germany
Background: The optimal timing for heart transplantation (HTx) or implantation of a ven-
tricular assist device (VAD) in patients with end-stage heart failure is a key issue.
Methods: In 86 patients with end stage heart failure requiring inotropic support and
scheduled for HTx or VAD implantation blood was sampled daily. Big endothelin-1 (big
ET-1) and natriuretic peptides (pro-ANP, ANP, NT-proBNP and BNP) were measured at
the end of the study. Clinical and hemodynamic parameters were also evaluated daily.
The patients were divided into groups with regard to the following endpoints: Group I –
immediate VAD placement due to profound cardiogenic shock on admission (n=10);
Group II – deterioration into cardiogenic shock after an initially stable clinical course
(n=26); Group III – stable clinical course allowed urgent HTx or VAD implantation (n=41);
Group IV – weaning from inotropic support (n=9). The data are presented as median val-
ues.
Results: On admission there were no differences in clinical parameters between the
